Large-scale proteomic identification of S100 proteins in breast cancer tissues

Patrizia Cancemi1,3, Gianluca Di Cara1, Nadia Ninfa Albanese1, Francesca Costantini1, Maria Rita Marabeti1, Rosa Musso1, Carmelo Lupo2, Elena Roz2, Ida Pucci-Minafra1,3*

Abstract

Background: Attempts to reduce morbidity and mortality in breast cancer is based on efforts to identify novel biomarkers to support prognosis and therapeutic choices. The present study has focussed on S100 proteins as a potentially promising group of markers in cancer development and progression. One reason of interest in this family of proteins is because the majority of the S100 genes are clustered on a region of human chromosome 1q21 that is prone to genomic rearrangements. Moreover, there is increasing evidence that S100 proteins are often up-regulated in many cancers, including breast, and this is frequently associated with tumour progression.

Methods: Samples of breast cancer tissues were obtained during surgical intervention, according to the bioethical recommendations, and cryo-preserved until used. Tissue extracts were submitted to proteomic preparations for 2D-IPG. Protein identification was performed by N-terminal sequencing and/or peptide mass finger printing.

Results: The majority of the detected S100 proteins were absent, or present at very low levels, in the non-tumoral tissues adjacent to the primary tumor. This finding strengthens the role of S100 proteins as putative biomarkers. The proteomic screening of 100 cryo-preserved breast cancer tissues showed that some proteins were ubiquitously expressed in almost all patients while others appeared more sporadic. Most, if not all, of the detected S100 members appeared reciprocally correlated. Finally, from the perspective of biomarkers establishment, a promising finding was the observation that patients which developed distant metastases after a three year follow-up showed a general tendency of higher S100 protein expression, compared to the disease-free group.

Conclusions: This article reports for the first time the comparative proteomic screening of several S100 protein members among a large group of breast cancer patients. The results obtained strongly support the hypothesis that a significant deregulation of multiple S100 protein members is associated with breast cancer progression, and suggest that these proteins might act as potential prognostic factors for patient stratification. We propose that this may offer a significant contribution to the knowledge and clinical applications of the S100 protein family to breast cancer.

Background

Breast cancer is still one of the most frequent forms of cancer in women. Unfortunately, the biological and clinical evolution of this type of cancer is not easily predictable since there are several types that behave differently among patients. This biological heterogeneity is consistent with observed varied responses to therapies across patient populations. For this reason the search for new biological markers to support prognosis and therapeutic options remains an open field in oncology research.

One class of proteins that is emerging as a potentially important group of markers in cancer development and progression is the S100 family. S100 are small, acidic-Ca\(^{2+}\) binding proteins, found exclusively in vertebrates. The first member was identified in the nervous system by Moore in 1965 [1]. The S100 name is based on the observation that they are soluble in 100% saturated ammonium sulfate at neutral pH; at least 25 members of the S100 protein family are recognized in human. Twenty one of them (S100A1-S100A18, trichohylin, filagrin, repeatin) are coded by genes clustered at

* Correspondence: idapucci@unipa.it
1 Dipartimento di Oncologia Sperimentale e Applicazioni Cliniche (DOSAC) Università di Palermo, Palermo, Italy
Full list of author information is available at the end of the article

© 2010 Cancemi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
chromosome locus 1q21 (known as the epidermal differentiation complex), while the other genes belonging to the subfamilies of S100B, S100P, S100Z and S100G, are respectively located at chromosome loci 21q22, 4p16, 5q14 and Xp22 [2]. S100 proteins form homo- and heterodimers, and even oligomers, and are expressed in tissue and cell-specific manner, suggesting that each S100 protein may perform different functions [3]. Indeed, it is well documented that S100 proteins are involved in several biological processes, such as cell cycle regulation, cell growth, cell differentiation and motility through a broad range of intracellular and extracellular activities [4-6]. Intracellular functions include regulation of protein calcium homeostasis, phosphorylation, regulation of cytoskeletal components and regulation of transcriptional factors. Extracellularly they act in a cytokine like manner through the receptor for advanced glycation end products (RAGE) [7].

The association between S100 family members and tumors may be explained by several observations: firstly, the region of human chromosome 1q21, where most of S100 genes are clustered, is prone to genomic rearrangements, likely supporting the tumor progression [8]; secondly, several S100 members show altered expression levels in cancer cells compared to normal cells and are differentially expressed in various malignancies, according to types and stages of cancer [9-15]. Finally, a number of S100 proteins have been shown to interact with and to regulate various proteins involved in cancer and exert different effects on p53 activity [16-20]. However, the occurrence, the role and the possible coordination of this group of proteins in breast cancer is still poorly known. In this study we describe a large-scale proteomic investigation performed on breast cancer patients for the screening of multiple forms of S100 proteins. The results have shown that the majority of S100 proteins were present at very low levels, if not absent, in the non-tumoral tissues adjacent to the primary tumor. The proteomic screening, extended to 100 cryo-preserved breast cancer tissues, showed that some S100 protein members were ubiquitously expressed in almost all patients, while others appeared more sporadic among the same group of patients. Most, if not all, of the detected S100 members appeared reciprocally correlated. More interestingly, patients which developed distant metastases after a three year follow-up showed a general tendency of higher S100 protein expression, compared to the disease-free group.

**Methods**

**Clinical specimens**

The present study was conducted on 100 surgical tissues of ductal infiltrating breast cancer collected between 2003 and 2007 in the Breast Unit of the La Maddalena Hospital. Research was carried out in compliance with the Helsinki Declaration with the patients’ written consent and with the approval of the Institutional Review Board (N°515/2008) from the La Maddalena Hospital. The study used leftover specimens, that is, aliquots of specimens collected for routine clinical care, and immediately frozen at -80°C until used. The specimens were not individually identifiable.

The patients of this study did not receive any cytotoxic/endocrine treatment prior to surgery. Diagnosis of ductal breast cancer (G2/G3) was confirmed histopathologically.

Post-operative monitoring to define whether or not distant metastases were present, was performed by conventional imaging follow-up, consisting of chest radiography, bone scintigraphy, magnetic resonance imaging (MRI) and positron emission tomography using 2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG-PET), as clinically indicated at La Maddalena Hospital.

**Sample preparations**

The frozen breast tissue samples were washed several times with phosphate-buffered saline and homogenized in RIPA buffer (50 mM Tris pH 7.5, 0.1% Nonidet P-40, 0.1% deoxycholate, 150 mM NaCl, 4 mM EDTA) containing a mixture of protease inhibitors (0.01% aprotinin, 10 mM sodium pyrophosphate, 2 mM sodium orthovanadate, 1 mM PMSF). The extraction was carried out overnight at 4°C with the same buffer. The total cellular lysate was centrifuged to remove tissue debris, and the resulting supernatant dialysed against ultrapure distilled water, lyophilized and stored at -80°C until use. The total protein concentration was determined by the Bradford method using bovine serum albumin as a standard [21].

**Two Dimensional Gel Electrophoresis**

The proteins extracted from breast cancer tissue and normal adjacent tissue were solubilised in a buffer containing 4% CHAPS, 40 mM Tris, 65 mM DTE in 8 M urea. Aliquots of 45 μg (analytical gels) or 1.5 mg (preparative gels) of total proteins were separately mixed with 350 μL of rehydration solution containing 8 M urea, 2% CHAPS, 10 mM DTE and 0.5% carrier ampholytes (Resolyte 3.5-10), and applied for IEF using commercial sigmoidal IPG strips, 18 cm long with pH range 3.0-10. The second dimension was carried out on 9-16% linear gradient polyacrylamide gels (SDS-PAGE), and the separated proteins were visualized by ammoniacal silver staining. Stained gels were digitized using a computing densitometer and analyzed with Image Master software (Amersham Biosciences, Sweden). Gel calibration was carried out using an internal standard and the support of the ExPaSy molecular biology server, as described [22].
Protein identification

N-Terminal microsequencing was performed by automated Edman degradation in a protein sequencer (Procise, 419 Applied Biosystems), as previously described [23].

Mass spectrometric sequencing was performed by Voyager DE-PRO (Applied Biosystems) mass spectrometer as described [24]. Briefly, proteins were digested using sequencing-grade trypsin (20 μg/vial). The tryptic peptide extracts were dried and redissolved in 10 μL of 0.1% trifluoroacetic acid (TFA). The matrix, R-cyano-4-hydroxycinnamic acid (HCCA), was purchased from Sigma-Aldrich. A saturated solution of HCCA (1 μL) at 2 mg/200 μL in CH3CN/H2O (50:50 (v/v)) containing 0.1% TFA was mixed with 1 μL of peptide solution on the MALDI plate and left to dry. MALDI-TOF mass spectra were recorded in the 500-5000 Da mass range, using a minimum of 100 shots of laser per spectrum. Delayed extraction source and reflector equipment allowed sufficient resolution to consider MH+ of monoisotopic peptide masses. Internal calibration was done using trypsin autolysis fragments at m/z 842.5100, 1045.5642, and 2211.1046 Da. Peptide mass fingerprinting was compared to the theoretical masses from the Swiss-Prot or NCBI sequence databases using Mascot http://www.matrixscience.com/. Typical search parameters were as follows: (50 ppm of mass tolerance, carboxamidomethylation of cysteine residues, one missed enzymatic cleavage for trypsin, a minimum of four peptide mass hits was required for a match, methionine residues could be considered in oxidized form.

Western Blotting

For immune detection the 1D-gels were electrotransferred onto nitrocellulose membrane (HyBond ECL, Amersham) and stained with Ponceau S (Sigma). The membranes were then probed with one of the following monoclonal antibodies: anti-actin (Oncogene), anti-S100A2, anti-S100A4, anti-S100A6, anti-S100A7, anti-S100A8 (Santa Cruz), or polyclonal antibodies: anti-S100A11, anti-S100A13 (SantaCruz). Following incubation with the appropriate peroxidase-linked antibody, the reaction was revealed by the ECL detection system, using high performance films (Hyperfilm ECL, Amersham).

Quantification and normalization methods

Quantitative expression levels were calculated as the volume of the spots (i.e. integration of optical density over the spot area). In order to correct for differences in gel staining, spot volumes relative to the sum of the volume of all spots an each gel (%Vol) were calculated by the software.

Since the cell densities within an area of the surgical sample, may be very variable among the different patients, measurements of relative expression levels of individual protein spots were normalized in each map for actin content [24] and the final value was designated as N%V. The relative abundance of silver stained actin was validated by western blot assays on the same tissue extract (Fig. 1).

For statistical analyses Ms Excel and Graph Pad Prism 4 software were used. Correlation of S100 protein members for breast cancer patients was performed using the Pearson correlation test. The difference in S100 expression between metastatic versus disease free patients was analyzed by unpaired F test. In all cases, p < 0.05 was considered significant (*), p < 0.01 highly significant (**), and p < 0.001 very highly significant (***)

Results

Proteomic identification of S100 proteins

In a previous work we reported the comparative proteomic profiles of proteins from 37 breast cancer surgical tissues [24]. Fig. 2 shows an updated proteomic map representative of a breast surgical tissue. The identified proteins are marked with labels corresponding to the access number of the Swiss-Prot database:

![Figure 1](image-url)
205 protein spots, corresponding to 114 distinct proteins, were identified in the maps. The protein identity was assessed by Maldi-Tof or N-Terminal microsequencing.

Fig. 3A shows the image of a gel window comprising an area covering a pI/kDa range of 4.5-7/15-9 kDa, where the majority of known members of S100 proteins are expected to localize.

After a comprehensive screening of protein spots included in this area, in different proteomic maps, we identified the following S100 protein members: S100A2 (protein S-100L), S100A4 (metastasin), S100A6 (Calcyclin, Prolactin receptor-associated protein), two isoforms, S100A7 (psoriasin), two isoforms, S100A8 (Calgranulin-A), S100A11 (Calgizzarin), three isoforms and S100A13 (S100 calcium-binding protein A13). Different isoforms of the same protein were labelled by alphabetic letters starting from the more acidic one. Fig. 3B illustrates the Maldi-Tof mass spectra of the corresponding spots shown in Fig. 3A. The list of identified proteins is shown in Table 1.

S100 proteins are preferentially expressed in the tumor mass
A group of 10 breast cancer tissues and their matched non tumoral counterparts were analyzed for comparative proteomic expression of the S100 proteins. Fig. 4 shows a panel of the cropped images from 2-D matched gels of the 10 selected patients. The S100 proteins are almost exclusively present in the tumor extracts, even though some S100 members are expressed at low, or very low levels, for example S100A2, S100A4 and S100A8. Fig. 5 shows box-plot graphs illustrating the quantitative variation of S100 protein expression levels between breast cancer and normal adjacent tissues. Significant differences were observed for all S100 protein members, except for S100A4 (expressed only in 5 patients) and for S100A6 (expressed also in normal tissues). Therefore these two proteins were not included in Fig. 5.

Proteomic distribution of S100 proteins within a cohort of 100 breast cancer patients
Fig. 6A shows a diagram illustrating the occurrence of the identified S100 protein members (abscissa) among
Figure 3 Identification of S100 proteins. A) Gel window comprising an area covering a pI/kDa range of 4.5-7/15-9 kDa, where the majority of known members of non-keratin associated S100 proteins, are expected to localize. The protein spots localizing in this area were picked from the gels and digested with trypsin. The resulting fragments were analyzed by mass spectrometry. Eleven spots were identified as S100 protein members. The numbers indicate the eleven spots corresponding to S100 proteins, whose spectra are shown in B). The mass peaks marked with an asterisk match the theoretical spectrum of the assigned proteins.
The 100 patients indicated from P01 to P100 (ordinate). The gray boxes indicate the absence of proteins in the map of the corresponding patient and the crosses indicate the patient expressing the given protein at its highest level. Interestingly, some proteins are expressed in almost all patients (S100A6, S100A11, S100A2 and S100A13); while others are expressed in a variable number of patients, i.e.: S100A8 in 71% of the patients, S100A4 in 57% and S100A7 in 51% (isoform a) and 63% (isoform b) (Fig. 6B).

In order to quantify the relative expression levels of individual S100 protein members the intensity of each protein spot was normalized for the actin content of the corresponding map. Fig. 7 shows the expression levels of each S100 protein, including isoforms, within the cohort of 100 patients. Except for S100A6, the average value of expression for each protein form (evaluated as N%V) does not exceed the relative abundance value of 0.25. The expression range of each S100 member is quite variable among patients: for instance, while the basic form of S100A6 ranges from 0.009 to 1.7, S100A4 ranges from 0.005 to 0.35.

### Relationship between expression levels of S100 members

The expression level of each S100 protein was cross-tabulated with the other protein members and statistical significance was assessed by the Pearson test. A significant association was observed for a high percentage of them (Fig. 8). More analytically, for S100 protein spots present as multiple isoforms, the more basic ones, having the closest pI to the theoretical values and likely representing the primary gene product, showed positive correlations with the other S100 members, except for S100A7 b and S100A8 that showed no correlation with the b-isoform of the S100A6 and with the S100A13.

### Western blot validation of S100 proteins

Immunological assays were performed to confirm the differential expression of all the S100 proteins identified in 2D-IPG. Validation with the appropriate antibodies, was performed on patient couples, chosen among the ones indicated by P01-P100 in the diagram in Fig. 5A, having high and low levels of the S100 proteins, respectively. Fig. 9 shows a panel of cropped 2 D gels containing the silver stained S100 protein spots, paired with the 1D-western blot image on the same tissue extract.

### Association of S100 members with tumor variables

The expression levels of S100 proteins were correlated with current clinical-pathological parameters which included age, tumor size, nodal status, immuno-cytoschemical presence of HER-2, oestrogen receptors, progesterone receptor, and Ki67 (Table 2). The results showed no significant correlations of the different S100 protein forms with tumor variables, except for S100A6 (isoform b) and S100A13 correlating with Ki67 (p =

---

**Table 1 Synopsis of the information on the identified S100 proteins**

| SPOT NUMBER | ENTRY NAME | SPOT NAME | AC | PROTEIN NAME | MOWSE SCORE | NUMBER OF MASS VALUES SEARCHED | NUMBER OF MASS VALUES MATCHED | (%) SEQUENCE COVERAGE | THEORETICAL MW (Da) - pl |
|-------------|------------|-----------|----|--------------|-------------|---------------------------------|------------------------------|-------------------------|-------------------------|
| 1           | S10A2      | S100A2    | P29034 | S100-A2      | 229         | 18                              | 16                           | 59                      | 11337-4.68             |
| 7           | S10A4      | S100A4    | P26647 | S100-A4      | 129         | 16                              | 10                           | 51                      | 11949-5.85             |
| 2           | S10A6      | S100A6 a  | P06703 | S100-A6      | 77          | 4                               | 4                            | 28                      | 10230-5.33             |
| 4           | S10A6      | S100A6 b  | P06703 | S100-A6      | 68          | 5                               | 4                            | 40                      | 10230-5.33             |
| 8           | S10A7      | S100A7 a  | P31151 | S100-A7      | 80          | 8                               | 5                            | 39                      | 11470-6.27             |
| 10          | S10A7     | S100A7 b  | P31151 | S100-A7      | 101         | 6                               | 6                            | 35                      | 11470-6.27             |
| 11          | S10A8      | S100A8    | P05109 | S100-A8      | 76          | 36                              | 8                            | 49                      | 10885-6.51             |
| 3           | S10A8      | S100A11 a | P31949 | S100-A11     | 82          | 5                               | 5                            | 42                      | 11847-6.56             |
| 5           | S10A8      | S100A11 b | P31949 | S100-A11     | 127         | 11                              | 11                           | 61                      | 11847-6.56             |
| 9           | S10A8      | S100A11 c | P31949 | S100-A11     | 73          | 6                               | 5                            | 34                      | 11847-6.56             |
| 6           | S10AD     | S100A13   | Q99584 | S100-A13     | 226         | 19                              | 13                           | 89                      | 11464-5.91             |

Entry names, protein names, accession numbers and theoretical MW and pl are from the Swiss-Prot database. Mowse score represent -10* Log (P), where P is the probability that the observed match is a random event. Number of mass value matched and the % of sequence coverage are given by Mascot database in the protein view session.
and for S100A11 (isoform a) correlating with nodal status (p = 0.021).

Association of S100 members with metastases
From several reports, individual S100 proteins have been found to correlate with metastasis; however a wide-ranging pattern of S100 protein members in a large scale of breast cancer patients was never screened before. Therefore, we analyzed our data set concerning the expression level of S100 proteins with respect to their association with the development of distant metastases. Patients with 3-year follow-up were fifty seven, 22 had developed distant metastases while 35 were disease-free. As shown in Fig. 10 the expression level of each S100 protein (expressed as average among patients of each group) was 1.07 to 2.13 fold higher in the

Figure 4 Panel of cropped areas of individual S100 protein spots from matched breast cancer tissues (BCT) and non tumoral adjacent tissues (NAT). The experiments were conducted on a pilot group of 10 patients, selected for the present study.
metastatic group. The unpaired F-test statistical method was used to detect expression variance among the S100 proteins in metastatic patients compared with the disease-free group.

Discussion

The clinical interest for S100 proteins as putative cancer biomarkers is continuously expanding. Major reasons for this are their multifunctional properties with a regulatory role in a variety of cellular and extracellular processes, and also the clustering of the majority of the S100 genes on a region of chromosome 1q21 which are often rearranged in cancer.

Although there are numerous reports on the correlation or involvement of individual S100 members in cancer [25-29], to our knowledge this study is the first to screen contextually for several members of the protein family through a large-scale proteomic approach. Proteomics is presently the only system able to detect protein isoforms of potential interest, which are not detectable by gene expression or immunohistochemical investigations [30-34]. Collectively we have identified eleven S100 protein forms, corresponding to 7 protein members. The first goal of this study was the finding of the almost exclusive expression of S100 proteins in cancerous breast tissues compared with normal adjacent tissues, an observation that per se substantiates the role of S100 proteins as putative biomarkers. This observation is in good agreement with literature data supporting the evidence that altered expression of many of S100 members occurs in several cancers including breast, lung, kidney, bladder, gastric, thyroid, prostate and oral cancers [see for review [29]].

The second goal of our study was the quali-quantitative proteomic screening of a significant number of the S100 family proteins among a large group of 100 breast cancer patients, all diagnosed as ductal infiltrating carcinomas.
Qualitative analysis showed that some of the S100 protein members are ubiquitously expressed in all patients while others appeared more sporadic. Among the first, are: S100A2, S100A6, S100A11 and S100A13 (all isoforms, when present); the members with more or less sporadic appearance are: S100A8 (71%), S100A4 (57%) and S100A7 (51%, isoform a and 63%, isoform b).

The quantitative evaluation showed that the expression levels of each S100 member was different among patients, but collectively, most of the S100 protein forms were statistically correlated. This adds complexity to the role of this protein category in breast cancer and suggests a possible common pathway of (dys-) regulation.

Finally, we investigated the prognostic potential of S100 proteins to predict distant metastatic relapse during a time lapse of three years from the surgical intervention. The most robust correlation with metastasis regarded primarily the protein S100A4, and secondly the protein S100A7. The S100A4, also named metastasin for its presumed role in metastasis promotion, is one of the most investigated in therecent literature [see for review [35]], as a promising biomarker of breast metastasis. Our results are in agreement with this hypothesis, since S100A4 expression level shows an increase of more than 2 fold in the metastatic group.

![Diagram of the relative intensities of the eleven S100 protein forms among the 100 patients. In abscissa are indicated the protein names and in the ordinate the density values. Bars indicate the mean of each protein expression level among patients.](http://www.biomedcentral.com/1471-2407/10/476)

**Figure 7**

![Association analysis of expression levels of S100 members evaluated as N%V. Statistical significance of the S100 members correlation was assessed by Pearson test and considered as significant, highly significant and very highly significant (*p < 0.05; **p < 0.01; ***p < 0.001). Correlation is indicated as Yes.](http://www.biomedcentral.com/1471-2407/10/476)

**Figure 8**

| Protein | Expression Level | p-value | r-value |
|---------|-----------------|---------|---------|
| S100A4  | YES             | p < 0.001 | r = 0.3916 |
| S100A6a |                 | p = 0.05 | r = 0.005 |
| S100A6b | YES             | p < 0.001 | r = 0.3893 |
| S100A7a |                 | p = 0.05 | r = 0.0154 |
| S100A7b | YES             | p < 0.001 | r = 0.3852 |
| S100A8  |                 | p = 0.05 | r = 0.1828 |
| S100A11a| YES             | p < 0.001 | r = 0.2664 |
| S100A11b|                 | p = 0.05 | r = 0.1648 |
| S100A13 |                 | p = 0.05 | r = 0.0517 |

**Table 1** Association analysis of expression levels of S100 members evaluated as N%V. Statistical significance of the S100 members correlation was assessed by Pearson test and considered as significant, highly significant and very highly significant (*p < 0.05; **p < 0.01; ***p < 0.001). Correlation is indicated as Yes.
Conclusions

Present data strongly support the hypothesis that a significant deregulation of multiple S100 family members is associated with breast cancer progression, and suggest that these proteins might act as potential prognostic factors for patient stratification. Although the patho-

Figure 9 Western Blot validation of S100 proteins detected by silver stain proteomics. The panel shows the cropped areas of 2D gels containing the silver stained S100 protein spots (left), paired with the 1D western blot image on the same selected breast cancer tissue (right). The validation was performed on two surgical samples for each S100-antibody, chosen among the 100 patient tissues showing respectively high and low levels of each S100 protein.

Table 2 Clinical-pathological characteristics of patients and correlation with S100 protein expression

| Age (n = 100) | S100A2 | S100A4 | S100A6 | S100A6 b | S100A7 | S100A7 b | S100A8 | S100A11 | S100A11 b | S100A11 c | S100A13 |
|--------------|--------|--------|--------|----------|--------|----------|--------|---------|-----------|----------|--------|
| ≤ 56         | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 |
| > 56         |        |        |        |          |        |          |        |         |           |         |        |
| T (n = 73)   | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 |
| 1            | 33%     |        |        |          |        |          |        |         |           |         |        |
| 2            |        | 56%    |        |          |        |          |        |         |           |         |        |
| 3            |        |        | 5%     |          |        |          |        |         |           |         |        |
| 4            |        |        |        | 6%       |        |          |        |         |           |         |        |
| N (n = 76)   | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 |
| Neg          | 39%     |        |        |          |        |          |        |         |           |         |        |
| Pos          | 61%     |        |        |          |        |          |        |         |           |         |        |
| HER-2 (n = 80) | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 |
| 0            | 45%     |        |        |          |        |          |        |         |           |         |        |
| 1            |        | 24%    |        |          |        |          |        |         |           |         |        |
| 2            |        |        | 14%    |          |        |          |        |         |           |         |        |
| 3            |        |        |        | 17%      |        |          |        |         |           |         |        |
| ER (n = 90)  | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 |
| Neg          | 31%     |        |        |          |        |          |        |         |           |         |        |
| Pos          | 69%     |        |        |          |        |          |        |         |           |         |        |
| PR (n = 89)  | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 |
| Neg          | 42%     |        |        |          |        |          |        |         |           |         |        |
| Pos          | 58%     |        |        |          |        |          |        |         |           |         |        |
| Ki67% (n = 77) | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 | p > 0.05 |
| ≤ 15%        | 23%     |        |        |          |        |          |        |         |           |         |        |
| 16-30%       |        | 29%    |        |          |        |          |        |         |           |         |        |
| > 30%        |        |        |        | 48%      |        |          |        |         |           |         |        |

Pearson t-test was used to evaluate the association among age, T, N, HER-2, ER and Ki67 and S100 proteins expression. *p < 0.05 was considered significant and marked in bold.
physiologic implications of the S100 proteins in cancer still require further clarification, the description of their differential occurrence in a large group of breast cancer patients, at proteomic levels, is a further important step promoting advancement of scientific knowledge for biomarker application in clinical practice.

Acknowledgements

This research is part of the project DIAMOL (Por Sicilia misura 3.4). Financial support was also given by Sx1000 contribution to COBS. Authors wish to thank Dr. I. Riili of the Breast Unit at La Maddalena Hospital, for providing clinical data.

Author details

1 Dipartimento di Oncologia Sperimentale e Applicazioni Cliniche (DOSAC), Università di Palermo, Palermo, Italy. 2 Ospedale La Maddalena D.O. III livello, Palermo, Italy. 3 Centro di Oncobiologia Sperimentale (COBS), Palermo, Italy.

Authors’ contributions

All authors participated in the interpretation and elaboration of the findings. IPM and PC were responsible for the conception and design of the study and drafted the manuscript. GDC performed the protein identification. NNA performed protein analysis. FC, MRM, RM carried out 2D-IPG. CL and ER contributed with clinical information. All authors have read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 3 March 2010 Accepted: 3 September 2010 Published: 3 September 2010

References

1. Moore BW. A soluble protein characteristic of the nervous system. Biochim Biophys Acta 1965, 19:730-744.
2. Santamaria-Kiesel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 2006, 396:201-214.
3. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999, 1450:191-231.
4. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003, 64:540-51.
5. Donato R. S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001, 33:637-68.
6. Heizmann CW, Fritz G, Schafer BW. S100 proteins: Structure, functions and pathobiology. Front Biosci 2002, 7:1356-68.
7. Ledecz E, Fritz G, Vetter SW, Heizmann CW. Binding of S100 proteins to RAGE: an update. Biochim Biophys Acta 2009, 1793:999-1007.
8. Salama I, Malone PS, MihaiMead F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008, 34:357-64.
9. Zhang H, Zhao G, Chen Y, Wang Y, Gao S, Mao Y, Li M, Peng A, He D, Xiao X. Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax 2008, 63:352-9.
10. Wang G, Wang X, Wang S, Song H, Sun H, Yuan W, Cao B, Bai J, Fu S. Colorectal cancer progression correlates with upregulation of S100A11 expression in tumor tissues. Int J Colorectal Dis 2008, 23:675-82.
11. Yang YQ, Zhang Li, Dong H, Jiang CL, Zhu ZG, Wu JX, Wu XL, Han JS, Xiao HS, Gao HJ, Zhang DQ. Upregulated expression of S100A6 in human gastric cancer. J Dig Dis 2007, 8:186-93.
12. Ohuchida K, Mizumoto K, Miyasaka Y, Yu J, Cui L, Yamaguchi H, Toma H, Takahata S, Sato N, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M. Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis. J Pathol 2007, 213:275-82.
13. Yao R, Davidson DO, Lopez-Beltran A, MacLennan GT, Montironi R, Cheng L. The S100 proteins for screening and prognostic grading of bladder cancer. Histol Histopathol 2007, 22:1025-32.
14. Ohuchida K, Mizumoto K, Yu J, Yamaguchi H, Komori H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M. S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples. Cancer Epidemiol Biomarkers Prev 2007, 16:649-54.
15. Moufayed N, Weichenthal M, Harder J, Wandel E, Sticherling M, Gläser R. Porosin (S100A7) is significantly up-regulated in human epithelial skin tumours. J Cancer Res Clin Oncol 2007, 133:253-61.
16. Kennedy RD, Gorksi JJ, Quinn JE, Stewart GE, James CR, Moore S, Mulligan K, Emberley ED, Loe TF, Mannison PJ, Mullan PB, Reid G, Johnston PQ, Watson PH, Harkin DP. BRCa1 and c-Myc associate to transcriptionally repress porosin, a DNA damage-inducible gene. Cancer Res 2005, 65:10265-72.
17. Emberley ED, Niu Y, Curtis L, Trup S, Mandal SK, Myers JN, Gibson SB, Murphy LC, Watson PH. The S100A7-C-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer. Cancer Res 2005, 65:5696-702.
18. van Dieck J, Fernandez-Fernandez MR, Veprintsev DB, Fersht AR. Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers. J Biol Chem 2009, 284:13804-11.
19. Stommel EP, Navert B, Leśniak W. S100A6 binds p53 and affects its activity. Int J Biochem Cell Biol 2009, 41:784-90.
20. Fernandez-Fernandez MR, Rutherford TJ, Fersht AR. Members of the S100 family bind p53 in two distinct ways. Protein Sci 2008, 17:1663-70.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
22. Pucci-Minafra I, Fontana S, Cancemi P, Albanese NN, Di Cara G, Marabeti MR, Marrazzo A, Minafra S. Proteomic patterns of cultured breast cancer cells and epithelial mammary cells. Ann N Y Acad Sci 2002, 963:122-39.
23. Pucci-Minafra I, Fontana S, Cancemi P, Basiricò L, Caricato S, Minafra S. A contribution to breast cancer cell proteomics: detection of new sequences. Proteomics 2002, 2:919-27.
24. Pucci-Minafra I, Cancemi P, Albanese NN, Di Cara G, Marabeti MR, Minafra S. New protein clustering of breast cancer tissue proteomics using actin content as a cellularity indicator. J Proteome Res 2008, 7:1412-8.
25. Wang H, Zhang Z, Li R, Ang KK, Zhang H, Caraway NP, Katz RL, Jiang F. Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer. Int J Cancer 2005, 116:285-90.
26. Semov A, Moreno MJ, Onuchichenko A, Abubrik A, Ball M, Ekel J, Pietrzynski G, Stanimirovic D, Alakhov V. Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmid formation. J Biol Chem 2005, 280:20833-41.
27. El-Rifa‘ W, Moskaluk CA, Abdabbdo MK, Harper J, Yoshida C, Riggins GJ, Friesen HF Jr, Powell SM. Gastric cancers overexpress S100A4 calcium-binding proteins. Cancer Res 2002, 62:6823-9.
28. Wang G, Zhang S, Fennig DG, Martin-Fernandez M, Rudland PS. Psoriasin (S100A7) is significantly up-regulated in human epithelial skin cancers. J Invest Dermatol 2003, 121:7-8.
29. Cross SS, Hamdy FC, Deloulme JC, Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 2005, 46:256-69.
30. Hsieh HL, Schafer BW, Saiani N, Heizmann CW. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun 2003, 307:375-81.
31. Jassim E, Serkeïs K, Dziadziovska R, Drozdowska A, Kobierska-Gulda G, Skowkowj J, Goźdź S, Urbaníak A, Sygut J, Jassim J. Prognostic value of S-100 immunostaining in tumour cells of non-small cell lung cancer. Biomarkers 2006, 11:262-9.
32. Ohuchida K, Mizumoto K, Ishikawa N, Fuji K, Komori H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res 2005, 11:7785-93.
33. Ohuchida K, Mizumoto K, Ohhaishi S, Yamaguchi H, Komori H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M. A putative tumor...
suppressor gene, is overexpressed in pancreatic carcinogenesis. Clin Cancer Res 2006, 12:5417-22.

35. Boye K, Maelandsmo GM: S100A4 and metastasis: a small actor playing many roles. Am J Pathol 2010, 176:528-35.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/476/prepub

doi:10.1186/1471-2407-10-476
Cite this article as: Cancemi et al.: Large-scale proteomic identification of S100 proteins in breast cancer tissues. BMC Cancer 2010 10:476.